For US residents only.

Where to Get Treatment


Where can I receive KYMRIAH?

After years of dedicated research and development, Novartis was the first to bring chimeric antigen receptor (CAR) T-cell therapy to its patients with KYMRIAH® (tisagenlecleucel). Now that this therapy is approved for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), select treatment centers across the United States are ready to begin administering KYMRIAH.


If you prefer to speak with someone to help you locate a treatment center or answer other questions about KYMRIAH, please call KYMRIAH CARES™ at 1-844-4KYMRIAH (1-844-459-6742) from 8:00 AM-8:00 PM ET.